8-K: Autonomix PoC Study Shows Durable Pancreatic Cancer Pain Relief

Autonomix Medical, Inc. announced new subgroup clinical data from its PoC study demonstrating rapid, durable, and meaningful pain relief in pancreatic cancer patients across all disease stages.

Summary

• New subgroup clinical data from the Proof-of-Concept 1 (PoC 1) study was presented at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium.
• The study evaluated pancreatic cancer patients with severe baseline pain treated using a transvascular RF denervation platform.
• Analysis stratified outcomes by cancer stage (Stage 2 through Stage 4) and revealed consistent pain reduction regardless of disease severity.
• Responding patients demonstrated a marked reduction in average pain within 24 hours following the procedure.
• At 7-days post-procedure, 93.75% of responding patients (N=16) improved from severe pain to mild or moderate pain, with some achieving near-elimination levels (score of 1 or 0 on VAS scale).
• At 46-weeks post-procedure, approximately two-thirds of responding patients (N=9) maintained pain at mild or elimination levels.
• At 3-months post-procedure, no responding patients (N=6) reported severe pain, and 50% maintained mild or eliminated pain levels.
• Meaningful improvement was observed even among late-stage (Stage 4) cancer patients, with several reporting transition from severe to mild or moderate pain, and sometimes near-elimination.

Sentiment

Score: 9

Explanation: The clinical data presented is highly positive, demonstrating significant and durable pain relief for a severe and undertreated condition (pancreatic cancer pain) across all disease stages. This represents a strong potential for the company's technology.

Positives

• Rapid onset of pain relief observed within 24 hours post-procedure.
• High percentage (93.75%) of responding patients achieved significant pain reduction (severe to mild/moderate) by 7 days.
• Demonstrated durability of pain relief, with two-thirds of responding patients maintaining mild or elimination levels at 46 weeks.
• Effective pain mitigation across all stages of pancreatic cancer, including late-stage (Stage 4) patients with limited treatment options.
• The technology offers a potential palliative impact for a debilitating and undertreated aspect of oncology care.

Negatives

• No explicit negative clinical outcomes or business setbacks were reported in this filing.

Risks

• Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations.
• Investors are urged to review cautionary statements and disclosures, including those under 'Risk Factors' in the Annual Report on Form 10-K filed with the SEC on May 29, 2025, and other SEC filings.
• The technology is investigational and has not yet been cleared for marketing in the United States.

Future Outlook

The company believes its targeted, nerve-based approach has the potential to provide meaningful relief for pancreatic cancer pain where traditional options fall short. The catheter-based microchip sensing array technology is considered a platform to address dozens of potential indications beyond pancreatic cancer, including cardiology, hypertension, and chronic pain management across a wide disease spectrum.

Management Comments

• Brad Hauser, President and Chief Executive Officer of Autonomix Medical, commented: 'Seeing patients move from severe pain to mild or near-elimination levels of pain, even in the most advanced stages of pancreatic cancer, is extraordinarily encouraging. These findings reinforce our belief that a targeted, nerve-based approach has the potential to provide meaningful relief when traditional pharmacologic and interventional options fall short.'

Industry Context

Pancreatic cancer pain is highlighted as one of the most debilitating and undertreated aspects of oncology care. Autonomix's nerve-targeted treatment offers a novel approach in an area where existing pharmacologic and interventional options often prove insufficient, potentially addressing a significant unmet medical need.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies, projects, or global benchmarks for pancreatic cancer pain treatments.

Stakeholder Impact

• **Patients:** Potential for significant improvement in quality of life through effective pain management for pancreatic cancer, including late-stage disease.
• **Shareholders:** Positive clinical data could enhance investor confidence and potentially lead to increased valuation due to the promising therapeutic potential.
• **Medical Community:** Introduction of a novel, targeted treatment option for a challenging clinical problem, potentially influencing future treatment paradigms.
• **Regulatory Authorities:** Successful clinical outcomes may support future regulatory submissions for market clearance.

Next Steps

• Continued clinical evaluation of the transvascular RF denervation platform.
• Further development of the platform technology for other potential indications, including cardiology, hypertension, and chronic pain management.

Key Dates

Recommendation

The clinical data from the PoC study is exceptionally strong, demonstrating rapid, durable, and meaningful pain relief for pancreatic cancer patients, a population with significant unmet medical needs and limited effective treatment options for pain. The technology's potential to address a debilitating condition across all disease stages, including late-stage, positions Autonomix for substantial market opportunity. While the technology is still investigational, these early results are highly encouraging and suggest a strong future outlook, warranting a 'strong buy' recommendation for investors seeking exposure to innovative medical device companies addressing critical healthcare challenges.

Keywords

Autonomix Medical, AMIX, pancreatic cancer, pain relief, clinical data, medical device, RF denervation, nerve-targeted treatment, ASCO GI, oncology, palliative care